metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
endometrial cancer endometrial cancer
versus placebo plus SoC
	pembrolizumab plus SoC
	NRG-GY018_pMMR, 2023 NCT03914612	RCT	endometrial cancer	pembrolizumab	placebo	Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. The patients were stratified into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease	295 / 296	low	conclusif	demonstrated 46 % decrease in progression or deaths (PFS) (PE) press realease 03/2024 : OS 0.79 [0.53; 1.17]not indexed in the results due to lack of information on the timepoint for this analysis
	NRG-GY018_dMMR, 2023 NCT03914612	RCT	endometrial cancer	pembrolizumab	placebo	Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. The patients were stratified into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease	112 / 113	low	conclusif	demonstrated 70 % decrease in progression or deaths (PFS) (PE) press realease 03/2024 : OS 0.55 [0.25; 1.19] not indexed in the results due to lack of information on the timepoint for this analysis